Table 1a Characteristics of the trial participants at baseline
Total (n=149) | ICL (−; n=94) | ICL (+; n=55) | P-value | |
|---|---|---|---|---|
Mean age–year | 70.8±10.0 | 70.7±9.6 | 70.9±10.7 | 0.920 |
Male sex–no. (%) | 100 (67.1) | 56 (59.6) | 44 (80.0) | 0.012 |
Mean BMI | 23.6±3.6 | 23.9±3.9 | 23.1±3.1 | 0.161 |
Acute Coronary Syndrome–no. (%) | 35 (23.6) | 18 (19.1) | 17 (31.5) | 0.109 |
Hypertension–no. (%) | 111 (74.5) | 69 (73.4) | 42 (76.4) | 0.846 |
Systolic BP | 130±22 | 126±21 | 136±22 | 0.006 |
Diastolic BP | 69±13 | 67±12 | 72±13 | 0.008 |
Diabetes–no. (%) | 76 (51.0) | 47 (50.0) | 29 (52.7) | 0.865 |
Dyslipidemia–no. (%) | 104 (69.8) | 67 (71.3) | 37 (67.3) | 0.712 |
Family history of CAD–no. (%) | 43 (28.9) | 24 (25.5) | 19 (34.5) | 0.265 |
Peripheral arterial disease–no. (%) | 34 (22.8) | 20 (21.3) | 14 (25.5) | 0.552 |
Chronic kidney disease–no. (%) | 70 (47.0) | 39 (41.5) | 31 (56.4) | 0.091 |
Current tobacco use–no. (%) | 18 (12.1) | 10 (10.6) | 8 (14.5) | 0.603 |
Previous MI–no. (%) | 21 (14.1) | 13 (13.8) | 8 (14.5) | 1.0 |
Coronary lesions–no. (%) | ||||
Single lesions | 50 (33.6) | 34 (36.2) | 16 (29.1) | 0.472 |
Triple or LMT lesions | 56 (37.6) | 36 (38.3) | 20 (36.4) | 0.862 |
Pre admission prescription of aspirin | 49 (32.9) | 34 (36.2) | 15 (27.3) | 0.284 |
Medication on discharge–no. (%) | ||||
Beta-blocker | 121 (81.2) | 76 (80.9) | 45 (81.8) | 1.0 |
ACE inhibitor or ARB | 98 (65.8) | 62 (66.0) | 36 (65.5) | 1.0 |
Statin | 140 (94.0) | 91 (96.8) | 49 (89.1) | 0.076 |
